BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen Y, Dong X, Wang Q, Liu Z, Dong X, Shi S, Xiao H. Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia. Front Pharmacol 2020;11:569843. [PMID: 33381028 DOI: 10.3389/fphar.2020.569843] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Yu H, Badhan RKS. The Application of Virtual Therapeutic Drug Monitoring to Assess the Pharmacokinetics of Imatinib in a Chinese Cancer Population Group. J Pharm Sci 2023;112:599-609. [PMID: 36202248 DOI: 10.1016/j.xphs.2022.09.028] [Reference Citation Analysis]
2 Chen Y, Zhang R, Mi D, Wang Q, Huang T, Dong X, Zhang H, Xiao H, Shi S. SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib. Gastric Cancer 2023;26:26-43. [PMID: 35999321 DOI: 10.1007/s10120-022-01332-7] [Reference Citation Analysis]
3 Cheng F, Zeng F, Li Q, Cui Z, Chen Y, Li W, Zhang Y. Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia. Cancer 2022. [PMID: 36181667 DOI: 10.1002/cncr.34478] [Reference Citation Analysis]
4 Liu Z, Zhang Z, Sun J, Li J, Zeng Z, Ma M, Ye X, Feng F, Kang W. Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis. Front Pharmacol 2022;13:966486. [DOI: 10.3389/fphar.2022.966486] [Reference Citation Analysis]
5 Shriyan B, Mehta P, Patil A, Jadhav S, Kumar S, Puri AS, Govalkar R, Krishnamurthy MN, Punatar S, Gokarn A, Khattry N, Gota V. Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia. Eur J Clin Pharmacol 2022. [PMID: 35652931 DOI: 10.1007/s00228-022-03345-8] [Reference Citation Analysis]
6 Hamza MS, Shouman SA, Abdelfattah R, Moussa HS, Omran MM. Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients. DDDT 2022;Volume 16:1595-1604. [DOI: 10.2147/dddt.s365646] [Reference Citation Analysis]
7 Corral Alaejos Á, Zarzuelo Castañeda A, Jiménez Cabrera S, Sánchez-Guijo F, Otero MJ, Pérez-Blanco JS. External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia. Br J Clin Pharmacol 2021. [PMID: 34705297 DOI: 10.1111/bcp.15122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Su PY, Tan BF, Fu CM, Chen CN, Chou AK, Kung PJ, Liao LC, Li MJ. Concurrence of imatinib-induced massive pleural/pericardial effusion and Campylobacter bacteremia in an adolescent with chronic myeloid leukemia. J Infect Chemother 2022;28:103-7. [PMID: 34649758 DOI: 10.1016/j.jiac.2021.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]